CD47/SIRPα axis: bridging innate and adaptive immunity

Area of Science:

• Immunology
• Cancer Biology
• Therapeutics

Background:

• Myeloid immune cells in the tumor microenvironment often suppress anticancer immunity.
• The CD47/SIRPα axis, an inhibitory receptor-ligand pair, mediates a 'don't eat me' signal, promoting immune evasion.
• CD47 is frequently overexpressed on cancer cells, making the CD47/SIRPα axis a therapeutic target.

Purpose of the Study:

• To review recent findings on how blocking the CD47/SIRPα axis enhances adaptive immune responses.
• To explore the interplay between myeloid CD47/SIRPα signaling and T cell-mediated antitumor activity.
• To discuss the therapeutic potential of CD47/SIRPα blockade in overcoming immunotherapy resistance, particularly in MHC-downregulated tumors.

Main Methods:

• Review of recent preclinical and clinical studies on CD47/SIRPα blockade.
• Analysis of the role of CD47/SIRPα in myeloid cell function and T cell activation.
• Investigation of CD47/SIRPα axis involvement in acquired resistance to cancer immunotherapy.

Main Results:

• Therapeutic blockade of CD47/SIRPα axis demonstrably improves adaptive immune responses against tumors.
• The CD47/SIRPα axis significantly influences the interaction between myeloid cells and T cells in the tumor microenvironment.
• Targeting CD47/SIRPα may offer a strategy to re-sensitize tumors resistant to conventional immunotherapy due to MHC downregulation.

Conclusions:

• Blockade of the CD47/SIRPα immune checkpoint holds significant therapeutic potential for enhancing cancer immunity.
• Understanding the complex interactions within the CD47/SIRPα axis is crucial for optimizing its clinical application.
• CD47/SIRPα-targeted therapies represent a promising avenue for overcoming immune evasion and immunotherapy resistance in cancer.